Protagonist Therapeutics, Inc. (PTGX)
Protagonist Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Newark, CA, US. The stock last traded at $152.15, up 2.60% on the session, giving a market capitalisation of $9.78B. On trailing twelve-month figures it carries a trailing P/E of 124.91, a net margin of 29.4%. Its beta of 1.79 implies it has historically moved more than the broad market.
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Protagonist Therapeutics, Inc. is most often compared with the following Healthcare names: